Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.21
Dollar change
+0.32
Percentage change
11.07
%
IndexRUT P/E- EPS (ttm)-1.56 Insider Own4.54% Shs Outstand145.08M Perf Week-3.60%
Market Cap465.74M Forward P/E- EPS next Y-1.08 Insider Trans-2.68% Shs Float138.51M Perf Month-22.65%
Income-225.25M PEG- EPS next Q-0.35 Inst Own95.41% Short Float6.11% Perf Quarter-37.18%
Sales170.28M P/S2.74 EPS this Y15.91% Inst Trans-3.09% Short Ratio5.76 Perf Half Y-43.09%
Book/sh2.13 P/B1.51 EPS next Y17.73% ROA-29.68% Short Interest8.46M Perf Year-61.04%
Cash/sh2.39 P/C1.34 EPS next 5Y21.60% ROE-58.31% 52W Range2.61 - 9.08 Perf YTD-34.49%
Dividend Est.- P/FCF- EPS past 5Y-32.91% ROI-42.62% 52W High-64.65% Beta1.23
Dividend TTM- Quick Ratio4.50 Sales past 5Y27.46% Gross Margin42.57% 52W Low23.22% ATR (14)0.27
Dividend Ex-Date- Current Ratio4.66 EPS Y/Y TTM-10.98% Oper. Margin-118.40% RSI (14)42.55 Volatility8.99% 7.83%
Employees709 Debt/Eq0.74 Sales Y/Y TTM-8.11% Profit Margin-132.29% Recom1.50 Target Price6.83
Option/ShortYes / Yes LT Debt/Eq0.71 EPS Q/Q-70.84% Payout- Rel Volume1.36 Prev Close2.89
Sales Surprise-5.51% EPS Surprise-44.88% Sales Q/Q-17.05% EarningsFeb 14 AMC Avg Volume1.47M Price3.21
SMA20-7.21% SMA50-14.16% SMA200-38.46% Trades Volume1,997,909 Change11.07%
Date Action Analyst Rating Change Price Target Change
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Oct-15-21Resumed Cowen Outperform
Mar-27-24 08:30AM
Mar-11-24 12:01AM
Feb-22-24 04:05PM
Feb-15-24 10:09AM
06:37AM
05:16PM Loading…
Feb-14-24 05:16PM
04:43PM
04:05PM
Feb-13-24 02:23AM
Feb-12-24 09:16AM
Jan-29-24 04:05PM
Dec-27-23 04:05PM
Dec-12-23 05:50AM
Dec-11-23 03:30PM
Dec-09-23 08:30AM
07:30AM Loading…
Dec-05-23 07:30AM
Nov-10-23 01:52PM
Nov-09-23 04:17PM
04:05PM
Nov-07-23 07:30AM
Nov-02-23 04:05PM
Oct-26-23 10:02AM
Oct-17-23 07:57AM
Sep-27-23 05:14AM
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
04:30PM
04:05PM Loading…
04:05PM
Jul-29-23 12:12AM
Jul-19-23 08:52AM
Jul-10-23 04:05PM
Jun-24-23 03:19PM
Jun-16-23 05:02PM
Jun-02-23 10:15AM
07:34AM
May-29-23 08:08AM
May-26-23 09:45AM
May-24-23 04:05PM
May-23-23 09:54AM
May-15-23 07:50AM
May-12-23 08:00AM
May-09-23 07:30AM
May-04-23 09:13AM
May-03-23 05:25PM
04:05PM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-25-23 04:05PM
Apr-24-23 09:40AM
Apr-18-23 12:10PM
Apr-12-23 07:30AM
Apr-06-23 04:05PM
Mar-29-23 04:20PM
Mar-27-23 09:40AM
Mar-16-23 11:41AM
Mar-10-23 10:42AM
10:26AM
Mar-09-23 09:55AM
09:40AM
Feb-28-23 11:11AM
Feb-27-23 04:05PM
Feb-24-23 11:52AM
Feb-21-23 09:55AM
09:40AM
Feb-14-23 05:55PM
04:05PM
Jan-30-23 07:21AM
Jan-23-23 04:05PM
Jan-10-23 09:00AM
Dec-27-22 04:05PM
Dec-20-22 06:14AM
Dec-10-22 10:00AM
Dec-05-22 07:30AM
Dec-01-22 07:30AM
Nov-21-22 04:05PM
07:30AM
Nov-03-22 06:35PM
04:05PM
Oct-11-22 08:05AM
Oct-05-22 04:05PM
Sep-15-22 06:48AM
Sep-14-22 05:22PM
Sep-12-22 08:30AM
Sep-02-22 08:00AM
Aug-14-22 11:13AM
Aug-04-22 12:00AM
Aug-03-22 05:35PM
04:05PM
Aug-02-22 10:07AM
Jul-28-22 10:02AM
09:48AM
07:30AM
Jul-27-22 10:01AM
Jul-18-22 06:56AM
Jul-08-22 04:05PM
09:08AM
Jun-16-22 12:49PM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEUPERT PETER MDirectorMar 12 '24Option Exercise0.8415,00012,600169,296Mar 13 05:55 PM
ROBINS CHAD MCEO and ChairmanMar 05 '24Sale3.4348,673167,0072,576,701Mar 06 07:40 PM
RUBINSTEIN JULIEPresidentMar 05 '24Sale3.4739,070135,764472,754Mar 06 07:41 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 05 '24Sale3.4429,390100,994327,415Mar 06 07:42 PM
PETERSON TYCHOChief Financial OfficerMar 05 '24Sale3.4415,45653,169531,553Mar 06 07:40 PM
LO FRANCISChief People OfficerMar 05 '24Sale3.4314,70050,439253,745Mar 06 07:42 PM
Taylor Stacy LSVP and General CounselMar 05 '24Sale3.4313,38145,963166,287Mar 06 07:42 PM
BOBULSKY SUSANChief Commercial Officer, MRDMar 05 '24Sale3.4412,99144,629248,290Mar 06 07:39 PM
PISKEL KYLEPrincipal Accounting OfficerMar 05 '24Sale3.437,72726,504123,318Mar 06 07:43 PM
NEUPERT PETER MDirectorDec 13 '23Option Exercise0.84100,00084,000122,968Dec 15 04:21 PM
PISKEL KYLEPrincipal Accounting OfficerNov 16 '23Sale4.132591,07087,305Nov 20 05:30 PM
SOOD NITINChief Commercial Officer, MRDAug 08 '23Sale6.5410,55068,997214,808Aug 08 04:53 PM
SOOD NITINChief Commercial Officer, MRDAug 07 '23Sale6.785,65238,321225,358Aug 08 04:53 PM
PETERSON TYCHOChief Financial OfficerJun 20 '23Option Exercise7.30134,961985,215534,180Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 20 '23Sale8.14134,9611,098,583399,219Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 15 '23Option Exercise7.3014,328104,594413,547Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 15 '23Sale8.5370,000597,100399,219Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 02 '23Sale7.1638,000272,080454,891Jun 06 04:23 PM
ADAMS R MARKChief Operating OfficerApr 11 '23Sale8.632,30819,918175,361Apr 12 06:04 PM
ADAMS R MARKChief Operating OfficerApr 10 '23Sale8.508176,944177,669Apr 12 06:04 PM